Formulation Development
Curia Wins 2023 Frost & Sullivan Customer Value Leadership Award
Curia recently announced it has been awarded a Best Practices Customer Value Leadership Award in the CRDMO industry by Frost & Sullivan. “We are very…
Berkshire Sterile Manufacturing Announces Plans to Expand Lyophilization Capacity
Berkshire Sterile Manufacturing (BSM) expects to double their lyophilization capacity for their fully automated, isolator-based filling line to meet new demand. A second lyophilizer will…
First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation
First Wave BioPharma, Inc. recently announced the final patient was dosed in the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation…
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
Harpoon Therapeutics, Inc. recently announced the completion of planned patient enrollment in the Phase 1 dose escalation study evaluating the safety, tolerability, and pharmacokinetics of…
Inozyme Pharma Announces Dosing of First Infant With ENPP1 Deficiency in Phase 1b Trial
Inozyme Pharma, Inc. recently announced dosing of the first patient in its ENERGY-1 trial, a Phase 1b clinical trial of INZ-701 in infants with ENPP1 Deficiency.…
MoonLake Immunotherapeutics Achieves Landmark Milestone With Positive Phase 2 Results for Nanobody Sonelokimab in Hidradenitis Suppurativa
MoonLake Immunotherapeutics recently announced positive top-line results from its global Phase 2 MIRA trial evaluating the efficacy and safety of the Nanobody sonelokimab in patients with moderate-to-severe….
Larkspur Biosciences Announces First-in-Class Program Targeting Novel B Cell Checkpoint
Larkspur Biosciences recently reported one of their lead programs is a first-in-class B cell checkpoint, TIM-1. This announcement follows the publication by Larkspur co-founder Vijay…
Clene Announces Publication of Phase 2 CNM-Au8 Clinical Data for the Treatment of ALS
Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc. recently announced The Lancet’s journal eClinicalMedicine has published combined detailed analyses of the Phase 2…
Ocean Biomedical Announces US Patent Issued for Bispecific Cancer Immunotherapy Treatment With Demonstrated Killing of Tumor Cells in Lung Cancer, Brain Cancer (Glioblastoma) & Metastatic Melanoma
Patent broadens protection around Ocean Biomedical’s first-in-class anti-CHi3L1 antibody to include new bispecific approaches targeting immune checkpoints, with potential application in….
XOMA Acquires Royalty & Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) & Phase 2 Oncology Asset
XOMA Corporation recently announced it has acquired the royalty and milestone rights associated with two assets from LadRx Corporation: arimoclomol, an oral therapeutic for Niemann-Pick…
ASLAN Pharmaceuticals Enters Strategic Licensing Deal With Zenyaku Kogyo for the Development & Commercialization of Eblasakimab
ASLAN Pharmaceuticals and Zenyaku Kogyo Co., Ltd., a subsidiary of privately held Zenyaku Holdings Co., Ltd. recently announced a strategic licensing agreement granting Zenyaku exclusive…
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
Eli Lilly and Company and DICE Therapeutics, Inc. recently announced a definitive agreement for Lilly to acquire DICE, a biopharmaceutical company that leverages its proprietary….
Lubrizol Licenses Award-Winning Apisolex™ Excipient to Welton Pharma to Develop a Novel Cancer Therapeutic
The Lubrizol Corporation recently announced the licensing of its novel excipient polymer technology, Apisolex™ excipient, to Welton Pharma (Welton). The license allows….
SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement With GSK
SCYNEXIS, Inc. recently announced the achievement of a $25-million performance-based development milestone under its exclusive license agreement with GSK for….
Sygnature Discovery Launches its LPS In Vivo Model to Profile Early Stage Anti-Inflammatory Drugs
Sygnature Discovery has established an in vivo LPS model of inflammation that can help understand life-limiting neuroinflammatory conditions like Parkinson’s disease, multiple sclerosis, Alzheimer’s disease,…
Mangoceuticals, Inc. Announces Upcoming Launch of its Sildenafil-Based Mango-Flavored Rapid Dissolve ED Product
Mangoceuticals, Inc. recently announced the upcoming release of its second Mango ED product leveraging the company’s existing custom compound alongside Sildenafil, which is the active…
Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded US Patent
Silo Pharma, Inc. recently announced the US Patent and Trademark Office (USPTO) has issued US Patent No. 16/825,371 titled Peptide-Targeted Liposomal Delivery for Treatment, Diagnosis,…
Croda Announces Two New Partnerships to Drive Sustainable Delivery Systems for the Pharmaceutical Industry
Croda International Plc recently announced it has signed two new partnership agreements that will help the pharmaceutical industry move toward a more sustainable supply chain for vaccine adjuvants…..
NodThera Announces Positive First-in-Human Data for Two Brain Penetrant NLRP3 Inflammasome Inhibitors
NodThera recently announced positive data from first-in-human studies of its lead therapeutic candidates, NT-0249 and NT-0796, and provides an update on the company’s priority clinical…
Ashland Announces Multifunctional Disintegrant for Improved Pharmaceutical Process Throughput
Ashland is introducing Polyplasdone Plus, a co-processed multifunctional direct compression superdisintegrant containing a glidant and lubricant. Saving time and simplifying development, the multifunctional disintegrant offers…
